공황장애에서 단기약물치료가 불안민감도와 삶의 질 및 기능장애에 미치는 영향 = Effect of Short-Term Pharmacotherapy on Anxiety Sensitivity, Quality of Life and Functional Disability in Panic Disorder Patients

국문 초록 (Abstract)

공황장애 환자에서 12주간의 escitalopram 약물치료 결과, 공황장애 증상은 관해 상태에 이르렀고, 높은 불안민감도와 삶의 질 저하 및 기능장애가 모두 유의하게 호전되었다. 하지만 공황장애 환자들은 약물치료 후에도 여전히 상대적으로 높은 불안민감도와 삶의 질 저하 및 기능장애를 보여서 이의 회복을 위해서는 장기간의 약물치료가 필요할 수 있겠다.

다국어 초록 (Multilingual Abstract)

Objective : Panic disorder is a chroni, debilitating illness, and has been known to be affected by high anxiety sensitivity and a poor quality of life. We examined if 12 weeks of pharmacotherapy with escitalopram could affect anxiety sensitivity, quality of life, and general disability in patients with panic disorder. Method : We enrolled 27 patients who met the DSM-IV-TR criteria for panic disorder, with or without agoraphobia, and completed 12 weeks of escitalopram treatment. We enrolled 29 normal control subjects who were matched for age and sex compared with the panic patients. All subjects were assessed using the Hamilton Rating Scale for depression (HAM-D), Hamilton Rating Scale for Anxiety (HAM-A), Panic Disorder Severity Scale (PDSS), Anxiety Sensitivity Index-Revised (ASI-R), WHO quality of life assessment (WHO-QOL) and Sheehan Disability Scale (SDS) before and after 12 weeks of treatment. Result : Panic disorder patients had a higher Anxiety sensitivity, a poorer Quality of life, and significant disability than normal control subjects at baseline. After the treatment, Panic disorder patients showed significant improvement in the severity of panic symptoms in terms of the HAM-A p<0.001), HAM-D (p<0.001) in addition, the reached a remission state in terms of the PDSS score. They also showed significant improvement in the ASI-R (p<0.001), WHO-QOL (p<0.001) and SDS (p<0.001), but mean scores of the ASI-R, WHO-QOL and SDS in panic disorder patients were did not reach normal levels. Conclusion : This study suggests that 12 weeks of pharmacotherapy with escitalopram could improve anxiety sensitivity, quality of life, and disability in panic disorder patients, although their anxiety sensitivity, quality of life and disability were not yet normalized after short-term pharmacotherapy. Thus, long-term pharmacotherapy may be necessary for panic disorder patients in order to get an optimal clinical response in terms of anxiety sensitivity, quality of life, and general disability.

참고문헌 (Reference)

1 박준영, "한국판 Sheehan Disability Scale의 신뢰도와 타당도 연구" 한국임상심리학회 29 (29): 73-81, 2010

2 김지혜, "한국어 확장판 불안 민감도 지수의 타당화 연구" 대한신경정신의학회 43 (43): 54-61, 2004

3 Schmidt NB, "The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress" 106 : 355-364, 1997

4 Shear MK, "The road to recovery in panic disorder: response, remission, and relapse" 59 (59): 4-8, 1998

5 Pollack MH, "The longitudinal course and outcome of panic disorder" 18 : 785-801, 1995

6 Reiss S, "The expectancy model of fear. In: Reiss S, Bootzin RR, editors. Theoretical issues in behavior therapy" Academic Press 107-121, 1985

7 Hamilton M, "The assessment of anxiety states by rating" 32 : 50-55, 1959

8 Bonacchi A, "Temperament and character traits associated with health-related quality of life in cancer patients" 98 : 377-384, 2012

9 Mahrer NE, "Relations between anxiety sensitivity, somatization, and health-related quality of life in children with chronic pain" 37 : 808-816, 2012

10 Scholten WD, "Recurrence of anxiety disorders and its predictors" 147 : 180-185, 2013

11 Rubin HC, "Quality of well being in panic disorder: the assessment of psychiatric and general disability" 57 : 217-221, 2000

12 Candilis PJ, "Quality of life in patients with panic disorder" 187 : 429-434, 1999

13 Davidoff J, "Quality of life in panic disorder: looking beyond symptom remission" 21 : 945-959, 2012

14 Markowitz JS, "Quality of life in panic disorder" 46 : 984-992, 1989

15 Katerndahl DA, "Quality of life and panic-related work disability in subjects with infrequent panic and panic disorder" 58 : 153-158, 1997

16 Park HJ, "Psychological characteristics of early remitters in patients with panic disorder" 197 : 237-241, 2012

17 Hayward C, "Predictors of panic attacks in adolescents" 39 : 207-214, 2000

18 Yates WR, "Phenomenology and epidemiology of panic disorder" 21 : 95-102, 2009

19 Hollifield M, "Panic disorder and quality of life: variables predictive of functional impairment" 154 : 766-772, 1997

20 Klerman GL, "Panic attacks in the community. Social morbidity and health care utilization" 265 : 742-746, 1991

21 Bandelow B, "Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo" 40 : 152-156, 2007

22 Barrera TL, "Impact of panic disorder on quality of life among veterans in a primary care pilot study" 54 : 256-261, 2013

23 Steven Reiss, "Expectancy theory of fear, anxiety, and panic" 11 : 141-153, 1991

24 Reiss S, "Expectancy model of fear, anxiety, and panic" 11 : 141-153, 1991

25 Noyes R Jr, "Environmental factors related to the outcome of panic disorder. A seven-year follow-up study" 181 : 529-538, 1993

26 Min SK, "Development of Korean version of WHO Quality of Life Scale Abbreviated Version (WHOQOL-BREF)" 39 : 571-579, 2000

27 Schmidt NB, "Anxiety sensitivity: prospective prediction of panic attacks and Axis I pathology" 40 : 691-699, 2006

28 Avallone KM, "Anxiety sensitivity, asthma control, and quality of life in adults with asthma" 49 : 57-62, 2012

29 Hazen AL, "Anxiety sensitivity and treatment outcome in panic disorder" 2 : 34-39, 1996

30 McNally RJ, "Anxiety sensitivity and panic disorder" 52 : 938-946, 2002

31 Taylor S, "An expanded anxiety sensitivity index: evidence for a hierarchic structure in a clinical sample" 12 : 463-483, 1998

32 Hamilton M, "A rating scale for depression" 23 : 56-62, 1960

33 Ehlers A, "A 1-year prospective study of panic attacks: clinical course and factors associated with maintenance" 104 : 164-172, 1995